Saltra HFA Inhaler 25+250mcg

Precaution

Pulmonary tuberculosis, severe cardiovascular disorders, diabetes, hypokalaemia, thyrotoxicosis. Paradoxical bronchospasm; discontinue immediately. Prolonged treatment with high doses increases risk of adrenal suppression and systemic Saltra HFA Inhaler 25 250mcg effects; monitor adrenal function. Monitor height of children on prolonged therapy. Consider additional steroid therapy during stress or surgery. Pregnancy, lactation. Withdraw gradually.

Indications

Regular treatment of asthma where long acting b2-agonist and inhaled corticosteroid is appropriate. Severe COPD. Dosage Adults: 2 inhalations twice daily at lowest effective inhaled corticosteroid dose. Children: under 4 yr, not recommended; over 4 yr, 2 inhalations of Salmicort 25/50 preparation twice daily.